India, Oct. 1 -- United Therapeutics Corporation (UTHR) announced that the U.S. District Court for the District of Delaware ruled in its favor in patent litigation involving Liquidia Technologies' Yutrepia an inhaled treprostinil therapy intended for patients with pulmonary hypertension associated with interstitial lung disease.
Pulmonary hypertension associated with interstitial lung disease (PH-ILD), is a serious lung disease that can impair a patient's ability to exercise and perform daily activities. Treatments that improve exercise capacity and breathing function are an important part of disease management.
The Court's decision relates to United Therapeutics' U.S. Patent No. 11,826,327, which covers methods of improving exercise capa...